Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Svitavy

9 clinical trials in Svitavy, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Svitavy at a glance
9
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

9 trials in Svitavy

Open in trial search

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Svitavy

What the registry says about research in the country

01 Dermatology Research

Innovative clinical studies focusing on moderate to severe plaque psoriasis, evaluating new therapeutic approaches for long-term management and treatment efficacy.

  • Treatment durability assessment
  • Safety and tolerability studies
  • Therapeutic response evaluation

Multiple trials are examining novel compounds to improve patient outcomes in chronic skin conditions.

02 Cardiovascular Medicine

Groundbreaking research targeting cardiovascular disease and its complications, with particular focus on lipoprotein management and prevention of major cardiac events.

  • Atherosclerosis prevention
  • Lipid-lowering therapies
  • Cardiovascular event reduction

Studies aim to reduce the risk of serious cardiovascular outcomes through innovative therapeutic approaches.

03 Cardiorenal Research

Advanced investigations into the relationship between heart failure and kidney function, evaluating combination therapies for improved patient outcomes.

  • Heart failure management
  • Kidney function preservation
  • Combined therapeutic approaches

Cutting-edge research exploring the effectiveness of dual-action treatments in complex cardiorenal conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.